Bonesupport Holding AB Share Price

Equities

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm 08:59:36 26/04/2024 pm IST 5-day change 1st Jan Change
232 SEK -2.36% Intraday chart for Bonesupport Holding AB -5.92% +23.27%

Financials

Sales 2024 * 857M 78.32M 6.53B Sales 2025 * 1.19B 109M 9.06B Capitalization 15.25B 1.39B 116B
Net income 2024 * 174M 15.9M 1.33B Net income 2025 * 311M 28.43M 2.37B EV / Sales 2024 * 17.5 x
Net cash position 2024 * 239M 21.85M 1.82B Net cash position 2025 * 488M 44.61M 3.72B EV / Sales 2025 * 12.4 x
P/E ratio 2024 *
89.2 x
P/E ratio 2025 *
48.8 x
Employees 118
Yield 2024 *
-
Yield 2025 *
0.42%
Free-Float 89.77%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.36%
1 week-5.92%
Current month+1.75%
1 month+2.65%
3 months+12.51%
6 months+63.73%
Current year+23.27%
More quotes
1 week
223.00
Extreme 223
255.00
1 month
221.40
Extreme 221.4
255.00
Current year
172.50
Extreme 172.5
255.00
1 year
94.65
Extreme 94.65
255.00
3 years
34.20
Extreme 34.2
255.00
5 years
19.05
Extreme 19.05
255.00
10 years
9.04
Extreme 9.04
255.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 01/18/01
Director of Finance/CFO 61 01/18/01
Chief Operating Officer - 01/21/01
Members of the board TitleAgeSince
Director/Board Member 66 -
Chairman 69 01/17/01
Director/Board Member 68 01/16/01
More insiders
Date Price Change Volume
26/24/26 232 -2.36% 260,598
25/24/25 237.6 -2.46% 283,373
24/24/24 243.6 -0.16% 115,250
23/24/23 244 -0.81% 84,320
22/24/22 246 -0.24% 127,304

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST

More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
232 SEK
Average target price
292.7 SEK
Spread / Average Target
+26.15%
Consensus

Quarterly revenue - Rate of surprise